DDInter810 DDInter1658
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Gefitinib {u} (Compound) resembles {v} (Compound) Erlotinib
Gefitinib {u} (Compound) treats {v} (Disease) lung cancer
Gefitinib {u} (Compound) binds {v} (Gene) CYP2D6
Gefitinib {u} (Compound) upregulates {v} (Gene) ZNF589
Gefitinib {u} (Compound) downregulates {v} (Gene) IFRD2
Gefitinib {u} (Compound) causes {v} (Side Effect) Appetite absent
Gefitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danazol
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Gefitinib (Compound) resembles Bosutinib (Compound)
Gefitinib (Compound) resembles Erlotinib (Compound)
Gefitinib (Compound) treats lung cancer (Disease)
Gefitinib (Compound) binds CYP2D6 (Gene)
Gefitinib (Compound) upregulates ZNF589 (Gene)
Gefitinib (Compound) downregulates IFRD2 (Gene)
Gefitinib (Compound) causes Appetite absent (Side Effect)
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene